Abstracts tagged "ANCA"

Abstract Number: 1670 • 2019 ACR/ARP Annual Meeting
Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)
Sohail Farshad¹, Alexandra Halalau ², Sayf Al-Katib ³, Julie George ⁴ and Elena Schiopu ⁵, ¹Department of Internal Medicine, Beaumont Health System, Royal Oak, MI, ²Department of Internal Medicine, Beaumont Health System, Royal Oak, ³Department of Radiology, Beaumont Health System, Royal Oak, MI, ⁴Beaumont Health System, Royal Oak, MI, ⁵Department of Rheumatology, University of Michigan, Ann Arbor
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is the most prevalent adult vasculitis and is associated with significant inflammatory burden; chest computed tomography (CT)…
Abstract Number: 2632 • 2019 ACR/ARP Annual Meeting
Changing Trends in the Management of ANCA-associated Vasculitis at an Academic Medical Center
Sana Afroz¹ and Najia Shakoor ², ¹RUMC, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: For years, cyclophosphamide (CYC) has been the primary treatment for severe anca-associated vasculitides (AAV) and has significantly improved disease related mortality. In addition, maintenance…
Abstract Number: 1672 • 2019 ACR/ARP Annual Meeting
Use of Rituximab for the Treatment of ANCA-Associated Vasculitis in Canada, 2010-2018
Arielle Mendel¹, Simon Carette ² and Christian Pagnoux ², ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Mount Sinai Hospital and University Health Network, Toronto, ON, Canada
Background/Purpose: Rituximab (RTX) is an effective therapy for ANCA-Associated Vasculitis (AAV). The Canadian Vasculitis Research Network (CanVasc) recommends RTX for induction among patients with unacceptable risk…
Abstract Number: 2633 • 2019 ACR/ARP Annual Meeting
Efficacy of Remission Induction Regimens in Elderly Patients with ANCA-Associated Glomerulonephritis
Audrey Hopkins¹, Stanley Chu ², Philip Seo ³, Eric Gapud ¹, Brendan Antiochos ¹, Shaker Eid ¹, Jason Liebowitz ¹ and Duvuru Geetha ¹, ¹Johns Hopkins Bayview Medical Center, Baltimore, ²Johns Hopkins University, Baltimore, ³Johns Hopkins Medicine, Baltimore, MD
Background/Purpose: Induction regimens using either cyclophosphamide (CYC) or rituximab (RTX) have been shown to have similar efficacy and similar rates of adverse events in randomized…
Abstract Number: 1675 • 2019 ACR/ARP Annual Meeting
A Retrospective Cohort Study Using Clinical Notes and Latent Topic Modeling to Characterize the Natural History of ANCA-Associated Vasculitis
Liqin Wang¹, Eli Miloslavsky ², John Stone ³, Hyon K. Choi ⁴, Li Zhou ⁵ and Zachary Wallace ², ¹Brigham and Women's Hospital, Boston, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is associated with end-organ damage, complications of treatment, and excess death. Retrospective studies on the clinical course of AAV, including the…
Abstract Number: 2634 • 2019 ACR/ARP Annual Meeting
ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients
Laura van Dam¹, Ebru Dirikgil ², Edwin Bredewold ², Argho Ray ², Ton Rabelink ², Cees van Kooten ² and Onno Teng ², ¹LUMC, Leiden, Zuid-Holland, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Recent studies have demonstrated that in patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) with successful remission-induction (RI) after cyclophosphamide (CYC), maintenance treatment with…
Abstract Number: 1678 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease in ANCA Associated Vasculitis: A Single Center Retrospective Analysis
Haidy Adel Youssef¹ and Mehrnaz Hojjati ², ¹Riverside Community Hospital/ UCR School of Medicine Internal Medicine Residency Program, Corona, CA, ²Department of Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: ANCA associated vasculitis patients have a wide spectrum of pulmonary involvement in the form nodular disease (especially peri-bronchial nodules), cavitating lesions, diffuse alveolar hemorrhage and less…
Abstract Number: 2637 • 2019 ACR/ARP Annual Meeting
Urine Complement Ba Levels During Flares of Renal Disease in Patients with ANCA-Associated Vasculitis
Salem Almaani¹, Christopher Toy ², Anna Levesque ², Lynn Fussner ¹, Alexa Meara ¹, Lianbo Yu ¹, David Cuthbertson ³, Simon Carette ⁴, Nader A. Khalidi ⁵, Curry L. Koening ⁶, Carol Langford ⁷, Carol A. McAlear ⁸, Larry Moreland ⁹, Christian Pagnoux ¹⁰, Philip Seo ¹¹, Antoine Sreih ¹², Steven Ytterberg ¹³, Paul Monach ¹⁴, Peter Merkel ¹², Brad Rovin ¹ and Dan Birmingham ¹⁵, ¹The Ohio State University Medical Center, Columbus, OH, ²Ohio State University, Columbus, OH, ³University of South Florida, Tampa, FL, ⁴Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Utah Hospital, Salt Lake City, UT, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, ⁹University of Pittsburgh, PITTSBURGH, PA, ¹⁰Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ¹¹Johns Hopkins Medicine, Baltimore, MD, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Brigham and Women's Hospital, Boston, MA, ¹⁵The Ohio State University Medical Center, Columbus
Background/Purpose: The alternative complement pathway has been implicated in the pathogenesis of ANCA-associated vasculitis (AAV). Change in markers of complement activation within patients have not…
Abstract Number: 1679 • 2019 ACR/ARP Annual Meeting
Adaptive Study Design of a Randomized, Multicenter, 2-Part Phase 2 Trial of Replacement of Glucocorticoids by IFX-1, a C5a Inhibitor, in Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Peter Merkel¹, Bernhard Hellmich ², David Jayne ³, Simon Rückinger ⁴, Zsuzsanna Tamas ⁵, Claus Thielert ⁵ and Othmar Zenker ⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, Kirchheim, Germany, ³Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ⁴Metronomia Clinical Research GmbH, Munich, Germany, ⁵InflaRx GmbH, Planegg, Germany, ⁶InflaRx GmbH, Jena, Germany
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are life-threatening rare autoimmune diseases are both forms of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Standard of…
Abstract Number: 2642 • 2019 ACR/ARP Annual Meeting
ANCA Testing: Final Diagnoses in Cases with Positive Immunofluorescence and Negative ELISA
‪Gabriel Breuer‬‏¹, Bashar Fteiha ¹, Alon Benaya ¹, Marwan Abu Sneineh‬‏ ¹ and Gideon Nesher ¹, ¹Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel
Background/Purpose: With the widespread availability of anti-neutrophil cytoplasmic antibody (ANCA) testing, interpreting positive results has become increasingly challenging. In addition to ANCA Associated Vasculitis (AAV),…
Abstract Number: 806 • 2019 ACR/ARP Annual Meeting
A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease
Rona Smith¹, David Jayne ² and Peter Merkel ³, ¹University of Cambridge, Cambridge, England, United Kingdom, ²Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ³University of Pennsylvania, Philadelphia
Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and relapse rates…
Abstract Number: 1680 • 2019 ACR/ARP Annual Meeting
Design of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of 2 Different Dose Regimens of IFX-1, a C5a Inhibitor, as an Add-On Therapy for Granulomatosis with Polyangiitis or Microscopic Polyangiitis
Peter Merkel¹, Bernhard Hellmich ², David Jayne ³, Simon Rückinger ⁴, Zsuzsanna Tamas ⁵, Claus Thielert ⁵ and Othmar Zenker ⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, Kirchheim, Germany, ³Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ⁴Metronomia Clinical Research GmbH, Munich, Germany, ⁵InflaRx GmbH, Planegg, Germany, ⁶InflaRx GmbH, Jena, Germany
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are life-threatening rare autoimmune diseases to anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Standard of care (SOC)…
Abstract Number: 2643 • 2019 ACR/ARP Annual Meeting
Comparative Study of Renal Transplantation Due to Rapidly Progressive Glomerulonephritis (RPGN): Study of 42 Patients from a Single Tertiary Centre
Lara Sanchez-Bilbao¹, Marina De Cos-Gomez ², Iñigo Gonzalez-Mazon ³, Belén Atienza-Mateo ¹, Jose Luis Martín-Varillas ¹, Mónica Calderón-Goercke ⁴, DIANA PRIETO- PENA ³, Juan Carlos Ruiz-San Millan ², Miguel A Gonzalez-Gay ¹ and Ricardo Blanco ¹, ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ²Nephrology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁴Hospital Marqués de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Rapidly Progressive Glomerulonephritis (RPGN) is characterized clinically by a rapid and severe decline in kidney function. Thus, this entity may lead to an end…
Abstract Number: 871 • 2019 ACR/ARP Annual Meeting
ANCA-Associated Vasculitis Management in the United States: Data from the RISE Registry
Zachary Wallace¹, Huifeng Yun ², Jeffrey Curtis ², Shuo Yang ², Lang Chen ², John Stone ³ and Hyon K. Choi ⁴, ¹Massachusetts General Hospital, Boston, ²University of Alabama at Birmingham, Birmingham, AL, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA
Background/Purpose: The management of ANCA-associated vasculitis (AAV) evolved substantially in recent years because of evidence supporting the efficacy of various treatment regimens. As such, treatment…
Abstract Number: 1681 • 2019 ACR/ARP Annual Meeting
The Association of Reduced Low-Density Lipoprotein (LDL) Cholesterol Levels with ANCA-Associated Vasculitis (AAV)
Zachary Wallace¹, Xiaoqing Fu ¹, Yuqing Zhang ², John Stone ³ and Hyon K. Choi ², ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) is a small vessel vasculitis associated with an intense inflammatory state. AAV patients are at a 2-fold higher risk of cardiovascular…

« Previous Page
1
…
5
6
7
8
9
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].